Tags: Drug.
Olaparib (AZD-2281) is an experimental chemotherapeutic agent developed by KuDOS Pharmaceuticals and later by AstraZeneca that is currently undergoing clinical trials. It is an inhibitor of poly ADP ribose polymerase (PARP) an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations which includes many ovarian breast and prostate cancers. Early Phase I trials were promising and olaparib underwent Phase II trials.
